SIGHT SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.34 USD | -8.09% |
|
-0.56% | +3.49% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 83.59M | Sales 2025 * | 94.01M | Capitalization | 266M |
|---|---|---|---|---|---|
| Net income 2024 * | -48M | Net income 2025 * | -40M | EV / Sales 2024 * | 2.3 x |
| Net cash position 2024 * | 73.74M | Net cash position 2025 * | 48.67M | EV / Sales 2025 * | 2.31 x |
| P/E ratio 2024 * |
-5.26
x | P/E ratio 2025 * |
-5.89
x | Employees | 214 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sight Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | -8.09% | ||
| 1 week | -0.56% | ||
| Current month | -3.78% | ||
| 1 month | +1.91% | ||
| 3 months | +29.61% | ||
| 6 months | +137.33% | ||
| Current year | +3.49% |
1 week
5.30
5.87
1 month
5.016.33
Current year
4.016.34
1 year
1.049.75
3 years
1.0442.57
5 years
1.0442.57
10 years
1.0442.57
| Managers | Title | Age | Since |
|---|---|---|---|
David Badawi
FOU | Founder | 54 | 09-12-31 |
Paul Badawi
FOU | Founder | 49 | 09-12-31 |
Alison Bauerlein
DFI | Director of Finance/CFO | 42 | 23-04-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Don Zurbay
BRD | Director/Board Member | 56 | 20-05-31 |
Erica Rogers
BRD | Director/Board Member | 61 | 19-10-31 |
Paul Badawi
FOU | Founder | 49 | 09-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | +11.05% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 5.34 | -8.09% | 167,183 |
| 24-05-16 | 5.81 | +4.68% | 48,938 |
| 24-05-15 | 5.55 | +1.83% | 74,785 |
| 24-05-14 | 5.45 | +0.55% | 92,821 |
| 24-05-13 | 5.42 | +0.93% | 104,597 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.
Calendar
2024-06-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
5.34
USD
Average target price
6.1
USD
Spread / Average Target
+14.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.49% | 266M | |
| -5.43% | 181B | |
| +4.30% | 114B | |
| -3.09% | 68.29B | |
| +5.86% | 52.24B | |
| +8.15% | 44.3B | |
| +7.52% | 42.73B | |
| +25.54% | 32.52B | |
| +17.85% | 26.02B | |
| +1.00% | 25.91B |
- Stock Market
- Equities
- SGHT Stock
